Correlation Between Ganglion Cell Layer Thinning and Poor Visual Function After Resolution of Diabetic Macular Edema

Sophie Bonnin, Ramin Tadayoni, Ali Erginay, Pascale Massin, and Bénédicte Dupas

Service d’Ophtalmologie, Hôpital Lariboisière, AP-HP, Université Paris 7-Sorbonne Paris Cité, Paris, France

Correspondence: Bénédicte Dupas, Service d’Ophtalmologie-Hôpital Lariboisière, 2 rue Ambroise Paré, 75010 Paris, France; benedict dupas@lrb.aphp.fr.
Submitted: August 19, 2014
Accepted: December 17, 2014
Citation: Bonnin S, Tadayoni R, Erginay A, Massin P, Dupas B. Correlation between ganglion cell layer thinning and poor visual function after resolution of diabetic macular edema. 2015;56:978–982. DOI:10.1167/iovs.14-15505

_The correlation between the central macular thickness (CMT) and the visual acuity (VA) is low in diabetic macular edema (DME). This is also observed after treatment: when intravitreal injections are effective in improving or normalizing the macular thickness of eyes with DME, even with normalized CMT, the VA does not systematically return to normal. The current paradigm relies on the identification of retinal damages responsible for visual impairment in DME. Most studies have focused on damages of outer retinal layers induced by DME, reporting associations between the loss of the inner segment-outner segment junction or external plexiform layer and the poor visual prognosis. Fewer studies have investigated inner retinal changes in DME, particularly, at the retinal ganglion cell (RGC) layer. Pelosini et al.5 studied the amount of tissue located between the two plexiform layers on “en face” OCT scans, and showed that the retinal tissue integrity may be used as an indicator of visual function before treatment.

Although the reliable identification of retinal structures on optical coherence tomography (OCT) images in the presence of retinal swelling remains difficult, assessing retinal layers on a “dried” retina after resolution of DME seems a valuable alternative.

The quantitative measurement of the ganglion cell-inner plexiform layer (GC IPL) thickness by spectral-domain OCT (SD-OCT) is now available, and is especially used in glaucoma studies. This automatic method allows reliably and objectively assessing GC IPL changes in the macula.

The aim of this study was to describe quantitative changes of the inner retina in eyes with resolved DME (r-DME) and in control diabetic eyes without DME (no-DME eyes), using the automatic OCT-based GC IPL measurement and to correlate these measurements with the VA.

Materials and Methods

In this retrospective study conducted in a tertiary eye care center (Lariboisière Hospital, Paris, France), records of consecutive diabetic patients with DME seen in the center and treated with intravitreal injections (anti-VEGF or steroids) over a 1-year period (June 2012–July 2013) were reviewed. Inclusion criteria were as follows: age older than 18 years, dried retina after treatment of DME, imaged with Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA, USA), with a CMT less than 315 µm, corresponding to normal value + 2 SDs: 277 + (2 × 19) µm, associated with restoration of foveal pit, and with normal thickness of six Early Treatment Diabetic Retinopathy Study (ETDRS) surrounding area.

Exclusion criteria were the following: any non–diabetes-related ophthalmological or neurological disease that could affect or could have affected the VA or visual field (amblyopia, strabismus, optic neuropathy, central serous retinopathy, ocular hypertensive crisis, previous vitreoretinal surgery, extensive cataract, uveitis, and ocular infections).

The OCT images were acquired at the time of the OCT measurement. Average GC IPL thickness was reduced in r-DME eyes compared with no-DME eyes (74 ± 14 µm versus 83.2 ± 6 µm, P = 0.0189), whereas no significant difference in mean CMT was observed (260.0 ± 34 µm versus 265.7 ± 22 µm, P = 0.847). Visual acuity significantly correlated with the average GC IPL thickness (r = 0.8, P < 0.0001) and minimum GC IPL thickness (r = 0.84, P < 0.0001) in r-DME eyes.

Conclusions. Despite favorable anatomic response and restoration of a CMT in the range of normal values after resolution of DME, the GC IPL thickness in r-DME eyes was lower than that in no-DME eyes and correlated with the VA. These results suggest that inner retinal alterations occurring in patients with DME and diabetic retinopathy may lead to visual deficiency persisting after treatment.

Keywords: diabetic macular edema, ganglion cell layer, optical coherence tomography
history of papilledema or glaucoma); ischemic maculopathy; recent panretinal photocoagulation (PRP) (<6 months); absence of ETDRS VA assessment; pathologic myopia (defined as myopia >6 diopters or fundus abnormalities); OCT scanning of poor quality, defined as scans with a signal strength less than 6 (maximum 10), not centered on the fovea, lack of uniform brightness, retinal nerve fiber layer (RNFL) discontinuity or misalignment, involuntary saccade or blinking artifacts, or presence of algorithm segmentation failure. Absence of segmentation errors or potential automated artifacts was manually checked for all scans included in the study. All data were assessed by a chart review, including sex, age, diabetes type and duration, serum glycated hemoglobin level (HbA1c), ETDRS best-corrected VA after refraction, IOP and previous ophthalmologic treatments (panretinal or macular grid photocoagulation, intravitreal injections). Fluorescein angiography was reviewed to confirm absence of ischemic maculopathy (defined by an enlargement of the foveal avascular zone >1000 µm in at least one diameter). The OCT images used to assess macular resolution were analyzed either 1 month after third ranibizumab intravitreal injection, or 2 months after dexamethasone intravitreal injection.

The control group (no-DME eyes) consisted of consecutive age-matched diabetic patients from an observational cohort followed during the same period in the same department, and with minimal or no diabetic retinopathy (DR) without any history of diabetic maculopathy, laser treatment, or intravitreal injections. Controls with an underlying comorbid ocular condition were excluded.

This study was approved by the Ethics Committee of the French Society of Ophthalmology (IRB 00008855 Societe Francaise d’Ophthalmologie IRB=1) and met the tenets of the Declaration of Helsinki. Informed consent was obtained for all patients.

### Optical Coherence Tomography

According to current practice, OCT scanning protocol was performed as follows, after pupil dilation, using the Cirrus high-resolution SD-OCT system: the macular cube protocol included macular thickness analysis and ganglion cell layer analysis (GCA). The GCA algorithm was included in the Cirrus HD-OCT 6.0 software. It detected and measured the macular GCIPL thickness within a 6 × 6 × 2 mm elliptical annulus area centered on the fovea. The algorithm has been described previously in detail. The size of the inner ring of the annulus was chosen to exclude the foveal area (vertical radius: 0.5 mm, horizontal radius: 0.6 mm), where the ganglion cell layer (GCL) is thin and difficult to detect. However, the dimension of the outer ring was selected to conform closely to the real anatomy of the macular region, where the GCL is the thickest in a healthy eye. The GCA reports the average GCIPL thickness over six sectorial areas (superotemporal, superior, superonasal, inferonasal, inferior, and inferotemporal) that form an elliptical annulus around the fovea, as well as the overall average for the annulus. The GCA also reports the minimum GCIPL thickness, which is the lowest GCIPL thickness over a single meridian crossing the annulus.

### Visual Function

Standard, high-contrast VA was assessed using ETDRS charts at 3.2 m as part of the standard follow-up of diabetic patients.

### Statistical Analyses

Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). Results are expressed as the mean ± SD. Continuous data were analyzed using the Mann-Whitney test for populations and the Fisher’s exact test was used to compare qualitative data. The Spearman test and simple linear regression analysis were used to test correlations between variables; P less than 0.05 was considered significant.

### RESULTS

#### Subjects

Twenty-one eyes of 19 diabetic patients with resolved DME after treatment for macular edema (r-DME eyes, defined by CMT <315 µm) and 21 eyes of 16 diabetic patients without maculopathy (no-DME eyes) were included in the study. Baseline characteristics are shown in Table 1. Among the r-DME eyes, 13 (62%) had been previously treated with ranibizumab, including seven eyes treated with combined focal laser and ranibizumab, and eight (38%) had previously received dexamethasone intravitreal implant (Dex-I), including three eyes treated with combined focal laser and Dex-I. Fourteen eyes (67%) had previously received PRP and the remaining eyes had nonproliferative DR.

All 21 of the no-DME eyes were phakic, and DR was mild or absent.

No significant difference was found between r-DME and no-DME eyes for age (P = 0.497*), sex (P = 1.0), and HbA1c (P = 0.059) (Table 1).

#### Assessment of the GCIPL Thickness in r-DME and no-DME Eyes

Table 2 shows the mean CMT and average GCIPL thickness in r-DME and no-DME eyes. Although no significant difference in mean CMT between both groups was observed, the average GCIPL thickness of the retina was significantly reduced in r-DME eyes. The assessment of the outer retinal thickness (full retinal thickness – GCIPL thickness) showed no significant difference between r-DME and no-DME eyes (186 ± 35 µm versus 183 ± 23 µm, P = 0.5208).

### Table 1. Baseline Characteristics of Studied Eyes

<table>
<thead>
<tr>
<th></th>
<th>No-DME Eyes</th>
<th>r-DME Eyes</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyes</td>
<td>21</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>60 ± 8.6</td>
<td>62 ± 8.8</td>
<td>0.497*</td>
</tr>
<tr>
<td>Sex, male/female</td>
<td>12/4</td>
<td>14/6</td>
<td>1.0†</td>
</tr>
<tr>
<td>VA, ETDRS letters</td>
<td>86.9 ± 3.4</td>
<td>64.4 ± 11.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Pseudophatic status</td>
<td>0</td>
<td>12 (57%)</td>
<td>0.0002†</td>
</tr>
<tr>
<td>Duration of diabetes, y</td>
<td>12.2 ± 6.4</td>
<td>19.9 ± 13.3</td>
<td>0.0667*</td>
</tr>
<tr>
<td>Diabetes type, 1/2</td>
<td>0/21</td>
<td>2/19</td>
<td>0.049†</td>
</tr>
<tr>
<td>Proliferative diabetic retinopathy stabilized after PRP</td>
<td>0</td>
<td>14 (67%)</td>
<td>&lt;0.0001†</td>
</tr>
<tr>
<td>Duration of DME, mo</td>
<td>N/A</td>
<td>33 ± 18</td>
<td></td>
</tr>
</tbody>
</table>

Values are presented as the mean ± SD.
* Mann-Whitney test.
† Fisher’s exact test.
Among the r-DME eyes, no significant difference in CMT or average and minimum GCIPL thicknesses was observed between eyes with and without previous PRP (Table 3). No significant difference in average and minimum GCIPL thicknesses was found between eyes with and without previous focal laser (Table 3).

**Relationship Between VA and OCT Measurements**

In r-DME eyes, the VA significantly correlated with the average GCIPL thickness ($r = 0.84; P < 0.0001$) and minimum GCIPL thickness ($r = 0.835; P < 0.0001$), whereas no correlation was found between the VA and the CMT ($r = 0.18; P = 0.45$). The Figure illustrates the simple linear regression between the minimum GCIPL thickness and the VA (Fig. A) and between the average GCIPL thickness and the VA (Fig. B) in r-DME eyes.

**DISCUSSION**

This study showed that GCIPL thicknesses were thinner in eyes with r-DME than in diabetic eyes without maculopathy, and that the average and minimum GCIPL thicknesses strongly correlated with the VA.

The quantitative assessment of macular structures is difficult to perform in case of macular swelling, and the originality of this work relied on the analysis of inner retina sectors in which there are normal or less affected areas, or persistent edema. This high correlation supports the hypothesis that the minimum GCIPL thickness is more accurate for detecting the RGC loss in diabetic maculopathy. This approach is not dependent on the average thickness of an area. Calculating the average thickness in a particular sector underestimates the local RGC loss in sectors in which there are normal or less affected areas, or persistent edema. This high correlation supports the hypothesis that the minimum GCIPL thickness is more accurate for detecting the RGC loss in diabetic maculopathy.

Although an association between outer retina abnormalities and the VA has been reported previously,

<table>
<thead>
<tr>
<th>TABLE 3.</th>
<th>Central Macular Thickness, and Average and Minimum GCIPL Thicknesses According to Previous Focal Laser or PRP in r-DME Eyes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No Focal Laser</strong></td>
<td><strong>Focal Laser</strong></td>
</tr>
<tr>
<td><strong>No PRP</strong></td>
<td><strong>PRP</strong></td>
</tr>
<tr>
<td>No. of eyes</td>
<td>10</td>
</tr>
<tr>
<td>Mean, μm</td>
<td>75.1</td>
</tr>
<tr>
<td>SD, μm</td>
<td>17.8</td>
</tr>
<tr>
<td>No. of values</td>
<td>7</td>
</tr>
<tr>
<td>Mean, μm</td>
<td>70.9</td>
</tr>
<tr>
<td>SD, μm</td>
<td>13.41</td>
</tr>
</tbody>
</table>

* Mann-Whitney test.
indicator of visual function before treatment. Our results highlight an interesting correlation between the GCIPL thickness and the VA, but do not imply a causative effect. Actually, although damages in the outer retinal layers were not assessed in this study, they could also contribute to the decrease in VA after resolution of DME. Of note, as mentioned in the Results section, outer retinal layer thicknesses were not significantly different between both groups.

Reasons for GCIPL thinning may be multiple, including vascular changes and primary neuronal degeneration. Intradetinal fluid accumulation by itself induces Muller cell ballooning and retinal degeneration. In addition, a diabetes-induced retinal neurodegeneration starts early after the onset of diabetes, even in the absence of notable vascular changes on fundus analysis, and could contribute to capillary degeneration. In a study conducted in patients with type 2 diabetes with minimal DR without history of DME, the mean GCIPL thickness measured using another method was 79.1 ± 11.1 μm, showing an early decrease in inner retinal layer thickness. Severe ischemia also could increase the ganglion cell degeneration, which is more severe in patients with more severe DR than in patients with mild retinopathy, as previously reported in animal models. The GCIPL thinning also could reflect previous poor glycemic control, rather than a recently balanced diabetes with HbA1c levels in r-DME eyes. Finally, potential toxic effects of intravitreal treatments on ganglion cells could occur. In this study, most eyes had previous history of many pharmacological treatments (steroids, anti-VEGF). It has been recently reported that ranibizumab suppresses the autocrine VEGF-induced survival of purified RGCs (Froger N, et al. IOVS 2014;55:ARVO E-Abstract 2391). Regarding the effects of previous laser treatment, in patients with previous macular photocoagulation, laser burns also could have reduced the GCIPL thickness in some sectors, affecting particularly the minimum GCIPL thickness. However, average and minimum GCIPL thicknesses according to previous focal laser or PRP in r-DME eyes were not different, and the small number of eyes does not allow further exploring this point. Transitory increases in macular GCIPL and peripapillary RNFL thicknesses throughout the 1-year post-PRP follow-up were found in a prospective, interventional case series study of 35 eyes. These data could be explained by PRP-induced retinal inflammation and edema in the early post-PRP phase, secondary to early glial cell activation. In our study, all patients had received previous PRP more than 6 months before, so that should not have affected our results.

Despite favorable anatomic response and restoration of a CMT in the range of normal values after resolution of DME, the GCIPL thickness was lower than normal and correlated with the VA. These results suggest that inner retinal alterations could be associated with DME and visual deficiency persisting even after treatment. Assessing the GCIPL thickness at the time of the edema and using it as a prognostic factor for visual recovery could be an interesting next step to investigate.

Acknowledgments

Supported by an independent research grant from Novartis Pharma SAS (Rueil Malmaison, France). The funding organization had no role in the design or conduct of this research. Preliminary results of this study were presented as a poster at the Association for Research in Vision and Ophthalmology annual meeting, May 4–8, 2014, Orlando, Florida, United States.

Disclosure: S. Bonnin, None; R. Tadayoni, Alcon (C, S), Alimera Sciences, Inc. (S), Allergan, Inc. (S), Bausch & Lomb (C, S), Bayer Schering Pharma (S), DORC (C), FCI-Zeiss (C, S), Novartis Pharmaceuticals Corporation (C, S), Pfizer (S), Takeda (C), Thrombogenics (C, S); A. Erginay, Allergan, Inc. (C), Novartis Pharmaceuticals Corporation (C, S); P. Massin, Allergan, Inc. (C, S), Novartis Pharmaceuticals Corporation (C, S); B. Dupas, Allergan, Inc. (C), Novartis Pharmaceuticals Corporation (C)

References


